Study of Daxdilimab (HZN-7734) in Patients With Moderate-to-Severe Primary Discoid Lupus Erythematosus
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
A Phase 2, double-blind, randomized, placebo-controlled parallel-group study to evaluate the
efficacy and safety of daxdilimab in participants with moderate-to-severely active primary
Discoid Lupus Erythematosus (DLE) refractory to standard of care.